List of Cinvanti drug patents

Cinvanti is owned by Heron Theraps Inc.

Cinvanti contains Aprepitant.

Cinvanti has a total of 9 drug patents out of which 0 drug patents have expired.

Cinvanti was authorised for market use on 09 November, 2017.

Cinvanti is available in emulsion;intravenous dosage forms.

Cinvanti can be used as treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy.

The generics of Cinvanti are possible to be released after 18 September, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

Drugs and Companies using APREPITANT ingredient

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CINVANTI before it's patent expiration?
More Information on Dosage

CINVANTI family patents

14

United States

3

Japan

1

Korea, Republic of

1

China

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic